Physician profile
Samuel Hahn
NPI 1982839635
$41,079.20
in general payments reported to CMS, 2019-2025
18 companies · $2,900 in 2025
The $2,900 reported for 2025 was more than what 92% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $523 · 2021: $4,273 · 2022: $3,505 · 2023: $3,051 · 2024: $26K · 2025: $2,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $8,072 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,589 · Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,125.00 |
| Travel and Lodging | $8,071.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,589.25 |
| Food and Beverage | $1,572.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24,196.52 | 2024 | Cardiomems |
| Allergan, INC. | $7,707.92 | 2019-2023 | |
| Abbvie INC. | $6,375.94 | 2023-2025 | |
| Revance Therapeutics, INC. | $770.23 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $703.77 | 2019-2025 | Dysport |
| Aerin Medical INC. | $518.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $275.74 | 2022-2025 | Dupixent |
| Optinose US, INC. | $110.72 | 2021-2024 | |
| Intersect Ent, INC. | $100.00 | 2019 | |
| Acclarent, INC | $94.74 | 2021 | |
| Medtronic, INC. | $59.79 | 2024 | Sinuva |
| Merz North America, INC. | $41.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.34 | 2023 | Cuvitru |
| Aimmune Therapeutics, INC. | $23.71 | 2022 | |
| Alk-Abello, INC | $23.44 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.10 | 2022 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Kls-Martin L.P. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.